Y-mAbs Announces Presentation of SADA Technology at AACR

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on developing and commercializing of novel antibody-based therapeutics for the treatment of cancer, today announced that a poster presentation featuring preclinical data from its GD2 SADA construct will be presented at the 2022 AACR Annual Meeting, which will be held in New Orleans, Louisiana from April 8-13, 2022.

Preclinical models have shown that the tetramerization function of the SADA domain appears to be important for the binding activity and antitumor effect of GD2 SADA. The data confirms that the SADA domain appears to increase tumor antigen binding, uptake, and persistence in tumor tissue, and markedly enhances antitumor responses in preclinical models.

The SADA technology has been licensed by the Company from Memorial Sloan Kettering (“MSK”) and the Massachusetts Institute of Technology. MSK researchers have developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs. MSK has institutional financial interests in the technology.

About Y-mAbs

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel antibody-based therapeutic cancer products. Besides conventional antibodies, the Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. The Company’s extensive pipeline of advanced products includes an FDA-approved product, DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and a registration-stage product candidate, omburtamab, which targets tumors that express B7-H3.

Forward-looking statements

Statements in this press release regarding future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our business model and our plans for product development, marketing and distribution; ongoing and future clinical and preclinical studies and our research and development programs; expectations related to the timing of the initiation and completion of regulatory submissions; regulatory, marketing and reimbursement approvals; rate and degree of market acceptance and clinical utility as well as pricing and reimbursement levels; retaining and hiring key employees; our sales, marketing and manufacturing capabilities and strategy; our intellectual property position and strategy; additional product candidates and technologies; strategic collaborations or partnerships and their potential benefits; expectations related to the use of our cash and cash equivalents, and the need, timing and amount of any future financing transactions; our financial performance, including our estimates of revenues, expenses, capital expenditure needs; developments relating to our competitors and our industry; and other statements that are not historical facts. Words such as ”anticipate” ”believe” ”contemplate” ”continue” ”could” ”estimate” ”expect” ”hope” ”intend ,” ”may” ”could” ”plans” ”potential” ”predicts” ”project” ”should” ”target” “will”, “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Our product candidates and associated technologies are novel approaches to treating cancer that present significant challenges. Actual results may differ materially from those indicated by these forward-looking statements due to a variety of factors, including, but not limited to: risks associated with our financial condition and our need for additional capital; risks associated with our development work; the cost and success of our product development activities and clinical trials; risks of delays in the timing of our regulatory submissions or failure to obtain approval for our drug candidates; risks associated with the commercialization of any approved pharmaceutical product, including the rate and degree of market acceptance of our product candidates; the development of our sales and marketing capabilities and the risks associated with the inability to obtain sufficient reimbursement for our products; risks related to our dependence on third parties, in particular for the conduct of clinical trials and the manufacture of products; our inability to enter into partnerships; risks relating to governmental regulation; market approval risks; risks associated with protecting our intellectual property rights; risks related to personnel issues and growth management; risks associated with our common stock, risks associated with the pandemic caused by the coronavirus known as COVID-19 and its variants such as Delta and Omicron, risks associated with Russia’s recent invasion of Ukraine and other risks and uncertainties affecting the Company, including those described in the “Risk Factors” section included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC and in our other documents filed with the SEC. All forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, events future or otherwise.

DANYELZA and “Y-mAbs” are registered trademarks of Y-mAbs Therapeutics, Inc.

Contact:

Y-mAbs Therapeutics, Inc.
230 Park Avenue, Suite 3350
New York, NY 10169
UNITED STATES

+1 646 885 8505

Email: [email protected]

Comments are closed.